SGLT2 inhibitor therapy is associated with IL-10/TGF-α/sVEGFR3 signalling and adipose tissue remodelling in advanced heart failure

Journal of Molecular and Cellular Cardiology Plus · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles